Russell Thomas, who has held senior roles at both organisations, takes on the joint CSO position as Symeres and Axxam push to offer clients a single pipeline spanning target screening to IND-ready drug candidates.
CDMO Adragos Pharma Kawagoe and Towa Pharmaceutical have agreed to a manufacturing partnership that will nearly triple solid-dosage capacity, shoring up Japan's fragile generics supply chain.
Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market.
IMCD has opened a new Pharmaceutical Technical Centre and Food & Nutrition Hub in Allendale, NJ — bringing labs, co-creation space, and global expertise together to speed up product development.
Digital Innovation: a key driver of competitiveness and sustainability across the pharmaceutical industry.
Biopharma has never lacked ambition. The gap has always been between scientific promise and a product on a shelf. That's exactly where the most consequential innovation is happening now.
AI in pharma has moved past the hype cycle and into implementation. The organizations that pull ahead won't have the most sophisticated models — they'll have the strongest evidence foundation underneath them.
The key to effective demand & supply planning in the pharmaceutical industry
Drug discovery generates enormous amounts of data, but turning it into meaningful insight is a major challenge.
Pharma 4.0 is high on every strategic agenda. Yet many struggle to turn digital ambitions into measurable results. Projects stall, systems don’t align, and valuable insights remain locked in fragmented data structures.
Shorter development cycles and complex active ingredients are demanding integrated solutions. Guided by the principle "Together – from lab to production," Fette Compacting positions its R&D Solutions as a partnership.
Marking 35 years of innovation, Enamine has grown from a regional supplier into one of the world's leading compound and service providers.
Lonza and Antharis Therapeutics announced an exclusive, target-specific licensing agreement to develop novel dual-payload ADCs targeting gastrointestinal (GI) cancers.
Recipharm announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharma and biotech companies with advanced sterile fill and finish services.
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking the Italian biopharmaceutical group's largest deal to date.
Siegfried has inaugurated a new large-scale API production facility at its German site in Minden.
Simulation Unlocks Capacity, Boosts Reliability, Drives Smarter Decisions
GSK has agreed to acquire US clinical-stage oncology specialist Nuvalent for $10.6 billion, its largest deal in years, to accelerate entry into lung cancer and boost growth through the dolutegravir patent cliff.
Axplora is repositioning its Italian Farmabios site on high-potency APIs as UDCA production moves to its FDA-approved Vizag facility in India, consolidating supply and scaling for global demand.
A clear signal to Berlin: the pharmaceutical companies Eli Lilly and Boehringer Ingelheim are canceling planned investments in Germany.
Sygnature Discovery has partnered with AI firm DaltonTx to sharpen its drug discovery pipeline, bringing faster medicinal chemistry decisions and tighter data privacy to its CRO offering.
Northway Biotech is finalizing the Baltic region's most advanced cell therapy center — a 3,500 m² facility at Vilnius City Innovation Industrial Park, set to open Q3 2025.
Precise, reproducible, and regulatory-ready: CE-based methods are redefining how scientists characterize therapeutic mAbs and ADCs across the biotherapeutic development pipeline.
Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Catalent partners with non-profit Elpida Therapeutics to support late-phase AAV manufacturing for a rare neurological gene therapy, securing exclusive rights across Elpida's broader AAV pipeline.
Hongene Biotech delivers end-to-end CDMO services for SiranBio's dual-target siRNA hepatitis B candidate, from raw materials through cGMP manufacturing, highlighting its capabilities in oligonucleotide therapeutics.
Bristol Myers Squibb licenses Lonza's SYNtecan linker-payload platform to advance an undisclosed ADC target, with Lonza eligible for upfront payments, milestones and royalties on resulting products.
Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
Symeres, a transatlantic CRDMO for drug discovery and development, announced the appointment of Henning Steinhagen as Chief Executive Officer.
Takeda has officially commissioned a new photovoltaic system at its production site in Oranienburg near Berlin.
Explore how pellet-based systems can de-risk development and scale-up of robust modified-release formulations across the product lifecycle.
All closing conditions satisfied for the acquisition of three small molecule sites in the US and Australia; closing to occur as of May 1, 2026. Adds highly demanded US-based manufacturing capacity to Siegfried's network.
In this CHEManager Leaders & Motivators interview, Frank Romanski, Lonza Capsugel, reflects on how strategy becomes execution and what resilience demands from teams,
India’s CDMO sector is rapidly advancing: stronger R&D, complex chemistry, digitalization, and efficiency gains. Astec boosts this with new R&D centers, automation, and global‑standard operations.
